Abstract:Characterization of the drug-target interactions is pivotal throughout the whole procedure of drug development. Most of the current assays, particularly, chromatographic methods lack the capacity to reveal drug adsorption on the muti-target surface. To this end, we derived a reliable and workable mathematical equation for revealing drug bindings to dual targets on the heterogeneous surface starting from the mass balance equation. The derivatization relied on the correlation of drug injection amounts with their retention factors. Experimental validation was performed by determining the binding parameters of three canonical drugs on a heterogeneous surface, which was fabricated by fusing angiotensin receptor type I and type II receptors (AT 1 R and AT 2 R) at the terminuses of circularly permuted HaloTag (cpHaloTag) and immobilizing the whole fusion protein onto 6-bromohexanoic acid modified silica gel. We proved that immobilized AT 1 R-cpHalo-AT 2 R maintained the original ligand- and antibody-binding activities of the two receptors in three weeks. The association constants of valsartan, candesartan, and telmisartan to AT 1 R were (6.26±0.14) × 10 5 , (9.66±0.71) × 10 5 , and (3.17±0.03) × 10 5 L/mol. In the same column, their association constants to AT 2 R were (1.25±0.04) × 10 4 , (2.30±0.08) × 10 4 , and (8.51±0.06) × 10 3 L/mol. The patterns of the association constants to AT 1 R/AT 2 R (candesartan>valsartan>telmisartan) were in good line with the data by performing nonlinear chromatography on control columns containing immobilized AT 1 R or AT 2 R alone. This provided proof of the fact that the derivatization allowed the determination of drug bindings on the heterogeneous surface with the utilization of a single series of injections and linear regression. We reasoned that is simple enough to model the bindings of drug adsorption on commercially available adsorbents in fundamental or industrial fields, thus having the potential to become a universal method for analyzing the bindings of a drug to the heterogeneous surface containing multiple targets.

Systematic Characterization of AT1 Receptor Antagonists with Label-Free Dynamic Mass Redistribution Assays.

Structural Basis for Ligand Recognition and Functional Selectivity at Angiotensin Receptor.

Structural Insights into Angiotensin Receptor Signaling Modulation by Balanced and Biased Agonists.

Structural Insights into Ligand Recognition and Activation of Angiotensin Receptors.

Pharmacophore Modeling of Dual Angiotensin II and Endothelin A Receptor Antagonists.

Phenotypic Assessment and Ligand Screening of ETA/ETB Receptors with Label-Free Dynamic Mass Redistribution Assay

Single-molecule Force Spectroscopy Study of Interactions Between Angiotensin II Type 1 Receptor and Different Biased Ligands in Living Cells

Delineating the Conformational Landscape and Intrinsic Properties of the Angiotensin II Type 2 Receptor Using a Computational Study

A systematic comparison of the properties of clinically used angiotensin II type 1 receptor antagonists

Label-free cell signaling pathway deconvolution of Angiotensin type 1 receptor reveals time-resolved G-protein activity and distinct AngII and AngIII\IV responses

Characterization of Angiotensin II Antagonism Displayed by Ib, a Novel Nonpeptide Angiotensin AT1 Receptor Antagonist

Characterizing the Binding Mechanism of Sparsentan to the Type-2 Angiotensin II Receptor Using AutoDock Vina

Exploring the role of the membrane bilayer in the recognition of candesartan by its GPCR AT1 receptor

Mapping Angiotensin II Type 1 Receptor-Biased Signaling Using Proximity Labeling and Proteomics Identifies Diverse Actions of Biased Agonists

Structure of the Angiotensin Receptor Revealed by Serial Femtosecond Crystallography

A chromatographic method for determining the interaction between a drug and two target proteins by fabricating a dual-heterogeneous surface

Characterization of the binding of angiotensin II receptor blockers to human serum albumin using docking and molecular dynamics simulation

Structural basis for selectivity and diversity in angiotensin II receptors

Antihypertensive Effects of a New Angiotensin Type 1 Receptor Antagonist I B on Rats

Pharmacological profile of YM358, a novel nonpeptide angiotensin AT1 receptor antagonist

Establishment and Application of High Throughput Screening Model for H1R Antagonists